Sleep Intervention for Teen Depression

N/A

Recruiting

Research Sponsored by University of California, San Francisco

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 65 years old

Must not have

Current use of medications or herbs with known effects on sleep

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to end of treatment (anticipated average exposure 2 months), months 8 and 14

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to test if improving the relationship between sleep patterns and waking time can help improve depression outcomes in teenagers with depression and disrupted sleep patterns. The trial will use a sleep intervention to target this issue

Who is the study for?

This trial is for adolescents with depression and misaligned sleep patterns, who are stable in their medical/psychiatric condition and not on medications or herbs affecting sleep. Those with active psychosis, bipolar disorder, drug dependence, or severe conditions like terminal cancer cannot join.

What is being tested?

The study tests if aligning biological circadian timing with wake time using a cognitive-behavioral sleep intervention can improve depression in adolescents. It's a confirmatory efficacy trial focused on this novel treatment target.

What are the potential side effects?

Since the interventions include TranS-C (a type of therapy) and psychoeducation (learning about mental health), side effects may be minimal but could include discomfort from discussing personal issues or changes in mood/sleep patterns.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am currently taking medication or herbs that affect my sleep.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to end of treatment (anticipated average exposure 2 months), months 8 and 14

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to end of treatment (anticipated average exposure 2 months), months 8 and 14

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to end of treatment (anticipated average exposure 2 months), months 8 and 14 for reporting.